Symptoms that arise as a consequence of systemic cancer treatment continue to be some of the most common and costly adverse effects of cancer therapy.
Our research aims to better our understanding of the mechanisms underpinning adverse effects and improving management of cancer treatment-related toxicity, particularly for the gastrointestinal tract. Acute gastrointestinal toxicity remain a significant challenge to delivering optimally effective cancer treatment with minimal impact on quality of life—which is the ultimate goal of excellent cancer care.
The Cancer Treatment Toxicities Group investigates chemotherapy, radiotherapy and targeted therapies, and the efficacy of new agents in prevention and treatment of toxicity. We are also interested in how toxicity of the cancer treatment links to other treatment symptoms, such has pain and cognitive decline.
In addition, our group has ongoing patient studies looking to determine the risk factors associated with poor cancer treatment outcomes and how to better predict adverse effects.
The Cancer Treatment Toxicities Group is comprised of three collaborative research laboratories: the Gastrointestinal Pathophysiology Laboratory led by Associate Professor Joanne Bowen, the Gut Microbiome Laboratory led by Professor Rachel Gibson, and the Clinical Pharmacogenomics Laboratory led by Dr Janet Coller.
Lead researcher: Associate Professor Joanne Bowen
- Professor Rachel Gibson - Co-Lead Researcher
- Dr Janet Coller - Co-Lead Researcher
- Professor Richard Logan
- Dr Hannah Wardill
- Kate Secombe
- Ghanyah Hamid Hussein Al-Qadami
- Elise Bruning
- Shu Yie Janine Tam
- Courtney Subramaniam
- Imogen Ball
- Dr Ysabella Van Sebille
- Anthony Wignall
- Dr Emma Bateman
We offer exciting opportunities for researchers at the honours, masters and PhD levels. Our research degrees are open to students from a broad range of backgrounds, and range from basic sciences to clinical research. If you are interested in human health, consider furthering your research career with us.